Journal of Antimicrobial Chemotherapy (2001) 47, 837-840
© 2001 The British Society for Antimicrobial Chemotherapy
Lung concentrations of telithromycin after oral dosing
a Departments of Medical Microbiology and Thoracic Medicine, City Hospital NHS Trust, Birmingham B18 7QH; b Department of Thoracic Medicine, Heartlands Hospital, Birmingham, UK; c Clinical Pharmacology, Aventis Pharma, Romainville, France
Concentrations of telithromycin were measured in plasma, bronchial mucosa (BM), epithelial lining fluid (ELF) and alveolar macrophages (AM) following multiple oral doses. Concentrations were determined using a microbiological assay. There were 20 subjects in the study, allocated to three nominal time periods: 2, 12 and 24 h. Mean concentrations in plasma, BM, ELF and AM for 2, 12 and 24 h were as follows: 2 h, 1.86 mg/L, 3.88 mg/kg, 14.89 mg/L and 69.32 mg/L; 12 h, 0.23 mg/L, 1.41 mg/kg, 3.27 mg/L and 318.1 mg/L; and 24 h, 0.08 mg/L, 0.78 mg/kg, 0.97 mg/L and 161.57 mg/L. These concentrations of telithromycin in BM and ELF exceeded for 24 h the mean MIC90s of the common respiratory pathogens Streptococcus pneumoniae (0.12 mg/L) and Moraxella catarrhalis (0.03 mg/L), as well as the atypical microorganism Mycoplasma pneumoniae (0.001 mg/L), and suggest that telithromycin may be effective for the treatment of community-acquired pneumonia and chronic obstructive pulmonary disease.
* Corresponding author. Tel: +44-121-507-5693; Fax: +44-121-551-7763.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Schmidt, R. Banks, V. Kumar, K. H. Rand, and H. Derendorf Clinical Microdialysis in Skin and Soft Tissues: An Update J. Clin. Pharmacol., March 1, 2008; 48(3): 351 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kiem and J. J. Schentag Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining Fluid Antimicrob. Agents Chemother., January 1, 2008; 52(1): 24 - 36. [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Johnston and R. J. Martin Chlamydophila pneumoniae and Mycoplasma pneumoniae: A Role in Asthma Pathogenesis? Am. J. Respir. Crit. Care Med., November 1, 2005; 172(9): 1078 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Fogarty, R. de Wet, L. Mandell, J. Chang, M. Rangaraju, and R. Nusrat Five-Day Telithromycin Once Daily Is as Effective as 10-Day Clarithromycin Twice Daily for the Treatment of Acute Exacerbations of Chronic Bronchitis and Is Associated With Reduced Health-Care Resource Utilization Chest, October 1, 2005; 128(4): 1980 - 1988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Zhanel, C. Johanson, N. Laing, T. Hisanaga, A. Wierzbowski, and D. J. Hoban Pharmacodynamic Activity of Telithromycin at Simulated Clinically Achievable Free-Drug Concentrations in Serum and Epithelial Lining Fluid against Efflux (mefE)-Producing Macrolide- Resistant Streptococcus pneumoniae for Which Telithromycin MICs Vary Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1943 - 1948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kasbekar and P. S. Acharya Telithromycin: The first ketolide for the treatment of respiratory infections Am. J. Health Syst. Pharm., May 1, 2005; 62(9): 905 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. S. Kuehnel, C. Schurr, K. Lotter, and F. Kees Penetration of telithromycin into the nasal mucosa and ethmoid bone of patients undergoing rhinosurgery for chronic sinusitis J. Antimicrob. Chemother., April 1, 2005; 55(4): 591 - 594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Gattringer, E. Urbauer, F. Traunmuller, M. Zeitlinger, P. Dehghanyar, P. Zeleny, W. Graninger, M. Muller, and C. Joukhadar Pharmacokinetics of Telithromycin in Plasma and Soft Tissues after Single-Dose Administration to Healthy Volunteers Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4650 - 4653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Zhanel, C. Johanson, T. Hisanaga, C. Mendoza, N. Laing, A. Noreddin, A. Wierzbowski, and D. J. Hoban Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations J. Antimicrob. Chemother., December 1, 2004; 54(6): 1072 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L Preston The Importance of Appropriate Antimicrobial Dosing: Pharmacokinetic and Pharmacodynamic Considerations Ann. Pharmacother., September 1, 2004; 38(9_suppl): S14 - S18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Reinert Clinical efficacy of ketolides in the treatment of respiratory tract infections J. Antimicrob. Chemother., June 1, 2004; 53(6): 918 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Muller-Serieys, J. Andrews, F. Vacheron, and C. Cantalloube Tissue kinetics of telithromycin, the first ketolide antibacterial J. Antimicrob. Chemother., February 1, 2004; 53(2): 149 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ackermann and A. C. Rodloff Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide J. Antimicrob. Chemother., March 1, 2003; 51(3): 497 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-I. Kadota, Y. Ishimatsu, T. Iwashita, Y. Matsubara, K. Tomono, M. Tateno, R. Ishihara, C. Muller-Serieys, and S. Kohno Intrapulmonary Pharmacokinetics of Telithromycin, a New Ketolide, in Healthy Japanese Volunteers Antimicrob. Agents Chemother., March 1, 2002; 46(3): 917 - 921. [Abstract] [Full Text] [PDF]
|
|